Amarin Corp Plc (AMRN)

[dukesking]

JL, Thanks. I agree with your post about lipids. I just read AVII's post from 2013 ADCOM vote and it sounds like all of the "NO" voters agree with your sentiments on lipid lowering not equating to CVD event reduction. They rightfully wanted and got their outcomes study. That should bode well for the upcoming ADCOM. Doesn't the entire prescription O3 market stand to lose on any failure of AMRN to receive a positive ADCOM vote and CVD label? I mean if Pharma is behind a concerted effort to derail AMRN, they would essentially be cutting their own throats. I can't imagine that they aren't in favor of a positive outcome so they can piggyback on it. The only winner might be the DS industry and I think that is who is behind the FUD campaign. I believe, as you and others have stated, that the FDA is only concerned over a very broad label and wants to get ADCOM opinions before granting the CVD label. All IMO.